ZAMP Bionews

The draft recommendations announced today by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials.

Tags: access programme, advanced breast cancer, capecitabine, chemotherapies, consultation document, draft guidance, draft recommendations, free survival, gsk, herceptin, innovative medicine, lapatinib, patient [...]

Breast cancer is the most common type of cancer and second leading cause of cancer-related death in women, in the United States. However, little is known about breast cancer in women in their early 40s and younger. Ann Partridge, MD, MPH, who founded and directs the Program for Young Women with Breast Cancer at Dana-Farber [...]

Doctors have long encouraged patients with diabetes to exercise regularly to help control their insulin levels and to maintain a healthy weight. Now, breast oncologists at Dana-Farber Cancer Institute in Boston are studying the relationship between exercise, weight, and insulin levels and the risk of breast cancer recurrence.

Tags: br, breast cancer, [...]

Of the estimated 1.4 million adults in the United States who will be diagnosed with cancer this year, approximately 25 percent will have a child 18 years or younger. For these parents, in addition to worrying about their own well-being, many will wonder about how and what to tell their children about their cancer and [...]

When anyone thinks of breast cancer, the face of a young woman doesn’t immediately come to mind. Yet, of the more than 200,000 women in the United States who will be diagnosed with breast cancer this year, about 11,000 will be under the age of 40.

Tags: Awareness, br, breast cancer, bri, [...]